立体定向放射治疗后仑伐替尼联合PD-1抑制剂治疗不可切除性大肝癌的疗效

Therapeutic effect of lenvatinib combined with PD-1 inhibitor on unresectable large hepatocellular carcinoma after stereotactic body radiotherapy

目的探讨立体定向放射治疗(SBRT)后仑伐替尼联合PD-1抑制剂治疗不可切除性大肝癌的近期疗效和毒副作用。方法收集10例SBRT后仑伐替尼联合PD-1抑制剂治疗的大肝癌患者的临床资料,采用mRECIST标准评价疗效,选择无进展生存期(PFS)作为研究的主要终点。结果10例患者均对治疗有反应,其中7例达到了部分缓解,客观有效率(ORR)为70%,疾病控制率达到100%。没有典型放射性肝损伤发生,CP评分进展6例。结论SBRT后仑伐替尼联合PD-1抑制剂治疗不可切除性大肝癌有良好的近期疗效,且毒副作用可控。

Objective To investigate the short-term efficacy and side effects of lenvatinib combined with PD-1 inhibitor in the treatment of unresectable large hepatocellular carcinoma(LHCC)after stereotactic body radiotherapy(SBRT).Methods Clinical data of 10 LHCC patients treated with lenvatinib combined with PD-1 inhibitor after SBRT were collected.Modified response evaluation criteria in solid tumors(mRECIST)was used to evaluate the therapeutic efficacy,and progression-free survival(PFS)was selected as the main endpoint of the study.Results Ten patients(100%)were responsive to the treatment,7(70%)achieved partial response,objective response rate(ORR)was 70%,and disease control rate reached 100%.No typical radiation-induced liver damage occurred,and Child-Pugh score increased in 6 cases(60%).Conclusion After SBRT,lenvatinib combined with PD-1 inhibitor has an ideal short-term efficacy in the treatment of unresectable LHCC,and the toxic and side effects are controllable.